In the Press
February 13, 2023

Contingencies for Biopharma, Medtech Deal Planning in a Down Market (Life Science Report)

For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clinical setting. In a down market, there are creative and thoughtful approaches companies can take to stand out as capital becomes more closely guarded and the competition becomes fierce. In this episode of Back Bay’s industry podcast, the Life Science Report, Jonathan Gertler speaks with Life Sciences partner Kristopher Brown about the current market landscape and how life science companies can recalibrate and prepare for capital raises—no matter the market outlook.